All-In U.S. Push for Vaccine Raises Risk Virus Will Linger

All-In U.S. Push for Vaccine Raises Risk Virus Will Linger

The U.S. strategy to rely on vaccines and treatments, rather than emphasizing social distancing, masks and testing nationwide, threatens to delay the return to normal life for Americans.

While the U.S. has committed more than $10 billion to develop new shots to fight Covid-19, about half of Americans say they are wary of taking them, according to a Gallup poll reported this month. Meanwhile, any shortfalls in the vaccine program could mean the country will struggle with the virus well into 2023, according to the London-based firm Airfinity Ltd.

At the same time, cases are climbing as the weather cools and more activity moves indoors. Hospitalizations have risen at least 10% in the past week in 32 U.S. states and the nation’s capital.

Other parts of the world are also in trouble. Some European countries are seeing more new infections each day than in the dismal spring outbreak. But those regions are considering re-instituting containment measures that have become anathema in the U.S. Parts of Asia, meanwhile, seem poised to recover faster.